Research programme: mesenchymal stem cell therapy - Apceth

Drug Profile

Research programme: mesenchymal stem cell therapy - Apceth

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator Apceth
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Glioblastoma; Graft-versus-host disease; Kidney disorders; Lung disorders; Solid tumours; Transplant rejection; Type 1 diabetes mellitus

Most Recent Events

  • 13 Jan 2017 Preclinical trials in Glioblastoma in Germany (IV)
  • 13 Jan 2017 Preclinical trials in Kidney disorders in Germany (IV)
  • 13 Jan 2017 Preclinical trials in Type-1 diabetes mellitus in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top